PMC:7195088 / 22173-22342
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
678 | 146-154 | Species | denotes | patients | Tax:9606 |
806 | 16-35 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
807 | 40-58 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
808 | 63-82 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
809 | 111-121 | Chemical | denotes | remdesivir | MESH:C000606551 |
945 | 160-168 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T108 | 160-168 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T248 | 16-35 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T249 | 16-25 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T250 | 26-35 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T251 | 40-58 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T252 | 63-82 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T253 | 63-72 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T254 | 73-82 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T255 | 88-98 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T256 | 99-103 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T257 | 111-121 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T163 | 0-169 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. |